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 Abstract 
Objective: The objective of this selective EBM review is to determine whether or not “Does 
metacognitive training (MCT) improve the quality of life in patients with schizophrenia?”  
 
Study Design: Systematic review of three randomized controlled trials (RCTs) published in 
peer-reviewed journals between 2010-2014, all in the English language; two of which were 
published in 2014 and one in 2010. 
 
Data Sources: Three randomized controlled trials found using PubMed. 
 
Outcomes Measured: Quality of life with a focus on social relationships was assessed using the 
Brief Quality of Life Questionnaire of the World Health Organization (WHOQOL-BREF) or 
Quality of Life Scale (QLS). 
Results: Briki et al. showed an improvement in the social initiatives variable on the QLS after 
MCT compared to the control group consisting of Supportive therapy (ST) and antipsychotic 
medications, however, data was not statistically significant (p-value >0.05). Moritz et al. 2010 
showed statistically significant improvement in social functioning after MCT compared to the 
control of treatment as usual (p-value = 0.03). Moritz et al. 2014 also showed an improvement in 
quality of life regarding the social variable when compared to the control of COGPACK + 
antipsychotic medications, however, the results were not statistically significant (p-value = 0.16). 
 
Conclusion: The articles analyzed in this EBM review claim MCT improves quality of life in 
patients with schizophrenia. Evidence from these studies are inconclusive on whether MCT 
improves social aspect of quality of life in patients with schizophrenia. Further studies 
incorporating larger sample size, sufficiently longer reassessment duration, and the effects of 
MCT on schizophrenia with comorbid substance abuse, are needed in order to determine the 
validity of MCT on improvement of quality of life in patients with schizophrenia.  
 
Keywords: Metacognitive training, schizophrenia, quality of life    
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Schizophrenia is a psychiatric disorder defined by symptoms of delusions, hallucinations, 
disorganized thinking or speech, abnormal motor behavior, and negative symptoms including 
diminished emotional expression, avolition, alogia, and lack of social interactions.1 
Schizophrenia often negatively affects a person’s quality of life and leads to a functional 
decline.2 The Downward Drift hypothesis suggests people with schizophrenia are unable to 
function well in society which results in placement of a lower socioeconomic status.2  
Schizophrenia affects approximately 21 million people worldwide.3  This disorder affects men 
and women equally but presents in the mid-to-early 20s in men and late 20s in women.2 
Generally, schizophrenia presents at the age of 15-55.2 Substance use is often comorbid in 
schizophrenia, with a substance of choice of nicotine followed by alcohol, cannabis and cocaine.2 
An analysis in 2013 showed an economic burden of schizophrenia to be estimated at $155.7 
billion domestically, with indirect costs comprising of $117.3 billion.4 Individual costs for a 
patient with schizophrenia is estimated to be $12,885 annually.5 In 2009-2011, approximately 
382,000 emergency department visits were related to Schizophrenia.6 With today’s political 
debates regarding mental health and stricter gun policies, a greater focus is projected towards 
treatment of psychiatric disorders in all medical settings. With this in mind, management and 
improvement in quality of life in patients with schizophrenia is relevant to the physician assistant 
(PA) profession.   
  The exact cause of schizophrenia is unknown but there is a strong genetic link.2 There is 
a 40% increased risk for an individual to have schizophrenia if both parents have schizophrenia 
and 12% increased risk if one first-degree relative has schizophrenia.2 It is hypothesized that 
schizophrenia is related to an imbalance in dopamine activity in different neuronal tracts in the 
brain.2 Decreased dopamine activity in the prefrontal cortical tract produces negative symptoms, 
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while increased dopamine activity in the mesolimbic tract produces positive symptoms in 
schizophrenia.2 Patients with schizophrenia also have decreased gamma-aminobutyric acid 
(GABA) and decreased levels of glutamate receptors (NMDA receptors) in the hippocampus.2 
  Currently there is no cure for schizophrenia, but symptoms are managed with a 
multimodal approach using antipsychotic medications combined with cognitive behavioral 
therapy.2 Second generation antipsychotics decrease negative symptoms to a greater extent and 
are preferred over first generation antipsychotics due to better side effect profile.7 Cognitive 
behavioral therapy combines cognitive therapy and behavioral therapy and allows for the patient 
to understand how their feelings and behavior are affected by their thoughts.2 A combination of 
pharmacologic treatment with therapy is currently the most effective therapy in the management 
of schizophrenia.2  
  While antipsychotics are the most effective at decreasing symptoms of schizophrenia, 40-
60% of patients remain significantly impaired.2 Alternative modalities are proposed to better 
improve quality of life for these patients. Metacognitive training (MCT) is a psychotherapeutic 
training module that targets cognitive errors and problem-solving biases involved in psychotic 
symptoms seen in schizophrenia.8 Patients with schizophrenia who lack insight in their own 
pathology have comparatively worse social functioning.9 Improving cognitive biases and 
symptomology of schizophrenia should improve social functioning. This paper evaluates three 
randomized controlled trials evaluating the efficacy of MCT. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “ Does 
metacognitive training improve the quality of life in patients with schizophrenia?” 
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METHODS 
  Three randomized controlled trials (RCTs) were used in this review. The population 
studied included patients in Europe between the ages of 18-65 with a Diagnostic and Statistical 
Manual of Mental Disorders 4th edition (DSM- IV) criteria for diagnosis of Schizophrenia 
spectrum disorder. The intervention used in all three studies was metacognitive training (MCT) 
sessions. Total sessions of MCT varied between each study. The control groups consisted of 
either neuropsychological training (COGPACK) in addition to the use of antipsychotic 
medications, supportive therapy (ST) with the use of antipsychotic medications, or treatment as 
usual (TAU).  
  Each study analyzed in this review was found using keywords “schizophrenia,” 
“metacognitive training,” and “quality of life” in the PubMed database. All articles were 
published in the English language in peer-reviewed journals. These RCTs were chosen based on 
relevance to the clinical question and had patient oriented outcomes (POEMs). The inclusion 
criteria for this review were RCTs analyzing patient oriented outcomes published after 2007. 
Studies were excluded from this review if studies did not analyze quality of life or if systematic 
reviews were published with the caveat of RCTs published after given systematic review. The 
statistical data reported in these studies include p-values, F score, and mean change from 
baseline. 
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Table 1: Demographics & Characteristics of Included Studies 
Study Type # 
of 
Pts 
Age 
(yrs) 
Inclusion criteria Exclusion 
criteria 
W/D Interventions 
Briki9 A 
multicenter 
randomized 
controlled 
trial 
68 18-
65 
-Age 18-65 
-DSM-IV 
criteria of 
schizophrenia 
spectrum 
disorder  
-persistent 
hallucination or 
delusions 
intellectual 
disability, 
poor fluency 
in French, 
DSM-IV 
criteria for 
substance 
abuse, unable 
to give 
consent 
14 Metacognitive 
training (MCT) 
sessions 1 hour, 
twice a week for 8 
weeks; a total of 
16 sessions 
Moritz S 
(2010)10  
Randomized 
controlled 
trial 
36 18-
65 
-age 18-65, 
schizophrenia 
spectrum 
diagnosis 
-age lower 
than 18 or 
higher than 
65, IQ <70, 
and 
inadequate 
command of 
the German 
language 
N/A 8 MCT sessions 
lasting 45-60 min 
per session 
Moritz 
(2014)11 
2-center, 
randomized, 
controlled, 
assessor- 
blind, 
parallel 
group trial 
150 18-
65 
-age 18-65, 
DSM-IV criteria 
for 
schizophrenia 
spectrum 
disorder 
according to the 
Mini-
international 
Neuropsychiatric 
Interview with a 
present or prior 
episode if 
delusional 
symptoms 
-substance 
dependence, 
IQ <70, 
severe organic 
brain damage, 
scores of 5 or 
higher on 
PANSS 
hostility item 
and of a 6 or 
higher on the 
PANSS 
suspiciousness 
item 
42 MCT sessions of 
45-60 min for a 
total of 16 
sessions 
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OUTCOMES MEASURED 
  All three studies analyzed changes in quality of life, primarily social life, reported by 
patients using a Quality of Life scale (QoL). In the Briki et al. study, the social aspect of quality 
of life was assessed using the Quality of Life Scale (QLS).9 Participants answered eight specific 
items regarding the social variable of QoL. QLS was scored using a 6-point scale ranging from 
0-5. Patients were assessed initially (less than 4 weeks before MCT) and at the end of training 
(less than 4 weeks after MCT).9 
  Moritz et al. 2010 also assessed the social aspect of QoL using Brief Quality of Life 
Questionnaire of the WHO (WHO-QoL-BREF).10 The WHO-QoL BREF analyzed physical, 
psychological, social health, and environment. Items were scored 1-5, with 1 representing very 
dissatisfied and 5 representing very satisfied. Participants were assessed on the final MCT 
session.10  
Moritz et al. 2014, analyzed the social variable of quality of life using WHO-QoL-BREF. 
Participants were assessed before MCT sessions and at 4 weeks, 6 months, and 3 years after 
MCT sessions.11  
RESULTS 
 All three RCTs assessed the efficacy of MCT on patients with schizophrenia. In Briki et 
al., 68 in-and outpatients with schizophrenia from university and psychiatric hospitals in France 
were enrolled in this study.9 Only 50 participants were assessed in the post-test due to refusal for 
follow-up or inadequate MCT sessions.9 All patients were on antipsychotic medications which 
were converted to chlorpromazine equivalents. Patients with comorbid substance abuse were 
excluded from the study.9 Participants were randomized into two different groups, either MCT 
(n=25) or the control (supportive therapy) (ST) (n=25) using an internet interface and QoL was 
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assessed using QLS.9 The assessor was blind for the randomization.9 Participants were assessed 
at baseline (T0) and after 8 sessions of MCT (T1).9 Briki et al. showed an improvement in the 
social initiatives variable on the QLS after MCT but data was not statistically significant.9 No 
improvement was found in the social circles variable.9 Data reported was analyzed using 
ANCOVA and is displayed in Table 2. 
Table 2: Briki et al. Mean Scores Pre and Post MCT9  
 Control (ST) (n=25) MCT (n=25)    
 T0(mean) T1(mean) T0(mean) T1(mean) F-score Mean 
change 
from 
baseline 
p-values 
Social 
circle 
2.48 2.48 2.48 2.04 4.48 -0.44 <0.05 
Social 
initiatives  
2.28 2.00 1.36 1.88 1.70 0.52 >0.05 
 
 In the Moritz et al. 2010 study, 36 participants from in-and outpatient programs for 
chronic schizophrenia in Germany were enrolled in this study.10 Patients with substance abuse or 
dependence were not excluded and comprised of 53% of participants in this study.10 Participants 
were assigned to either MCT group (n=18) or the control group which was treatment as usual 
(TAU) (n=18) by a statistician and were kept blind to trainers and assessors.10 Both groups had 
100% completion rate. QoL was assessed at baseline and after 8 weeks of MCT.10 The control 
group (TAU) received MCT after the reassessment.10 Moritz et al. 2010 showed significant 
improvement in social functioning after MCT compared to the control (TAU).10 Data was 
analyzed using covariate and t(32)=2.23 and p-value= 0.03.10  
In Moritz et al. 2014, 150 participants with schizophrenia from in-and outpatient facilities 
in Germany were enrolled in this study.11 Patients with comorbid substance dependence were 
excluded from the study.11 Patients were randomly assigned to either MCT (n=76) or the control 
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(COGPACK) (n=74). Assessors were kept blind to group assignment.11 Participants were 
assessed at baseline, at 4 weeks, 6 months, and 3 years after MCT.11 In the MCT group, 72 
people participated in the 4 week reassessment while 4 refused.11 The control group had 63 
people at the 4 week reassessment while 11 people refused.11 At the 6 month follow-up, 67 
people were reassessed while 5 refused in the MCT group.11 The control group had 62 
participants and only 1 refusal. At the 3 year follow-up, only 47 people were reassessed for the 
MCT group and 45 people were reassessed in the control group.11 Completion rate at the 3 year 
follow-up was 61.3%.11 This study showed an improvement in quality of life regarding the social 
variable, but data was not statistically significant (p-value= 0.16).11 The values discussed were 
analyzed using ANCOVA and are displayed in Table 3.  
 Table 3: Moritz et al. 2014 Treatment Outcomes11 
 Mean    
 MCT Group (n=76) Control group 
(COGPACK) (n=74) 
P-
value 
F-
score 
Mean 
change 
from 
baseline 
 Pretreatment Follow-
up 
Pretreatment Follow-
up 
   
Social 
QoL 
51.33 55.37 49.14 50.39 0.16 1.98 4 
 
DICUSSION 
  Schizophrenia is a psychiatric disorder characterized by symptoms of delusions, 
hallucinations, disorganized thinking or speech, and lack of social interactions.1 Schizophrenia 
often negatively impacts quality of life and leads to a functional decline.2 Although 
antipsychotics are the most effective at decreasing symptoms of schizophrenia, many remain 
significantly impaired.2 Alternative outlets, such as MCT, are proposed to better improve the 
quality of life for these patients. MCT is a new treatment program that is a mixture of cognitive-
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based therapy (CBT) and cognitive remediation (CRT) which work by changing cognitive 
thoughts that are involved with the formation of delusions.10 MCT is available online, for free, in 
35 different languages.8 MCT is performed in group setting with 3-10 patients per group. Each 
MCT session lasts 45-60 min with a total of 8 sessions for a full cycle.12 Although there are no 
harmful effects from MCT, there are a few limitations to this type of treatment. MCT is 
administered by a professional such as a practitioner or a psychotherapist.8 While MCT is free of 
charge to administer, patients are fiscally responsible for therapy sessions with their provider. 
Individuals who cannot work due to their illness, may find it hard to use this therapy. 
Furthermore, patients with schizophrenia must be willing to participate in training sessions 
which can involve many weeks.  
  This review analyzes if MCT improves social quality of life in patients with 
schizophrenia. Each article analyzed had limitations. The Briki et al. study showed an 
improvement in social initiatives but no improvement in the social circle variable.9 The study 
state patients showed a reduction in cognitive biases, particularly, with preoccupation.9 The 
authors justify an indirect improvement in the social aspects of quality of life by explaining how 
a reduction in preoccupation would allow for patients to be aware of their need for social 
relationships.9 Although this is a reasonable statement, more studies are needed before 
generalizing that MCT improves social relationships. A key limitation for this study was a 
relatively small sample size of 50 participants that were assessed for post-test effects. Not only 
did the study contain a small sample size, but participants were assessed at the end of 8 weeks; a 
duration of time that may not be long enough to foster new relationships or improve their social 
circle.9  
  Moritz et al. 2010 study also had similar limitations. This study showed significant 
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improvement in social functioning after MCT when compared to the control group.10 This study 
included a small sample size of 36 participants with a short reassessment period of 8 weeks.10 
This study also included participants with a comorbid diagnosis of substance dependence, a 
variable that was excluded from the other studies.10 Since the effects of MCT on substance 
dependence was not directly measured, the improvement in social functioning could be due to an 
improvement in substance dependence. Unlike the other studies, Moritz et al. 2010 did not 
mention if participants were concurrently on antipsychotic medications. Another limitation 
addressed in the Moritz et al. 2010 study was that patients in the TAU group, may have received 
information regarding MCT and may have indirectly benefited from the training.10  
  The Moritz et al. 2014 study also resulted in an improvement in quality of life regarding 
the social variable however, data was not statistically significant.11 The study accredits the 
improvement in quality of life to improvement in cognitive biases such as a reduction in jumping 
to conclusions and delusions.11 The authors state a reduction in these biases can improve social 
relationships overtime.11 Unlike the other studies in this review, Moritz et al. 2014, did have a 
larger sample size (n=150) and a longer follow-up duration of 3 years.11 Given the number of 
participants and duration of follow-up, this study is a good representation of whether MCT can 
improve social relationships. This study, however, was not without limitations. All participants 
in this study were on antipsychotic medications.11 The study failed to mention type of 
antipsychotic used, if these medications were standardized across all participants, and if 
medication compliance was an issue. The use of antipsychotics could skew the participants 
perception of improved quality of life. Although this study included a larger sample size, the 3-
year reassessment resulted in increased losses to follow-up and a completion rate of only 
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61.3%.11 In the end, only 47 participants from the MCT group and 45 participants from the 
control (COGPACK) were reassessed.11  
CONCLUSION 
  The articles analyzed in this EBM review claim MCT improves the quality of life in 
patients with schizophrenia. Evidence from these studies are inconclusive on whether MCT 
improves social aspect of quality of life in patients with schizophrenia. Two of the studies (Briki 
et al., Moritz et al. 2014) argue social life did improve, although data were not statistically 
significant.9,11 Moritz et al. 2010, showed improvement in the social aspect of quality of life that 
was statistically significant, however limitations such as small sample size, and the inclusion 
criteria of comorbid substance abuse could have skewed the results. 
  Further studies should include larger sample size during reassessment and a longer 
duration of time to assess for post treatment effects. The effects of MCT on improvement of 
substance abuse or dependence should be further investigated in order to properly evaluate 
participants with a comorbid diagnoses of schizophrenia and substance dependence.
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